Enzymatica AB (publ) (FRA:EN9)

Market Cap	63.48M -29.6%
Revenue (ttm)	4.98M +18.3%
Net Income	-4.79M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	50
Open	0.2300
Previous Close	0.2280
Day's Range	0.2300 - 0.2300
52-Week Range	0.1220 - 0.2940
Beta	n/a
RSI	51.72
Earnings Date	Apr 14, 2026

About Enzymatica AB

Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company’s product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Employees: 20
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EN9

Financial Performance

In 2025, Enzymatica AB's revenue was 53.90 million, an increase of 18.27% compared to the previous year's 45.58 million. Losses were -51.89 million, -2.42% less than in 2024.

Financial numbers in SEK